Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$15.0B
195M shares
52-week range
$58.89 – $89.83
56% from low
Sector
OPHTHALMIC GOODS
Exchange
NASDAQ
CS
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
www.coopercos.comNo one on the platform currently holds COO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 117,292 | $10.8M |
| Bridgewater Associatesas of 2026-03-31 | 6,111 | $436.9K |
| Execution date | Ratio |
|---|---|
| 2024-02-20 | 4-for-1 |
No one on the platform has traded COO yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.3B | +5.3% | $4.63 | $4.61–$4.67 | 16.4× | 11 |
| 2027 | $4.5B | +4.8% | $5.01 | $4.93–$5.08 | 15.2× | 11 |
| 2028 | $4.8B | +5.2% | $5.43 | $4.53–$6.17 | 14.0× | 8 |
| 2029 | $5.0B | +5.1% | $5.79 | $5.75–$5.85 | 13.1× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-06-04 | $1.10 | $1.21 | +10.0% |
| 2026-03-05 | $1.03 | $1.10 | +6.8% |
| 2025-12-04 | $1.11 | $1.15 | +3.6% |
| 2025-08-27 | $1.07 | $1.10 | +2.8% |
| 2025-05-29 | $0.93 | $0.96 | +3.4% |
| 2025-03-06 | $0.91 | $0.92 | +0.7% |
| 2024-12-05 | $1.00 | $1.04 | +4.0% |
| 2024-08-28 | $0.91 |
| $0.96 |
| +5.4% |
| $12.8B |
| — |
| NBIXNeurocrine Biosciences, Inc. | $150.82 | -3.62% | $15.2B | — |
| SMMTSummit Therapeutics Inc. | $14.00 | -7.28% | $11.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
The Cooper Companies, Inc. $COO (8h) Bullish Flow: Value-oriented funds are treating every consolidation retest near $75.00–$76.00 as an asymmetrical long entry, positioning for high-margin contact lens adoption (MyDay/MiSight) and international margin recovery to drive a swift push toward 52-week highs. 🐂 💧 Bull Key Level: $77.00 (Bull confirmation to hold above immediate pivot and keep buyers in full control) 🐂 🔥 Bear Key Level: $65.00 (Deeper macro demand floor for total structural invalidation) 🐻 ⚠️ Targets: $84.20 / $89.83 💰 🍺 Why: Volume profile analysis reveals an ironclad point-of-control accumulation shelf built between $70.00 and $75.00 that provides rock-solid downside protection. Respecting higher-low price structure keeps the setup primed for a swift squeeze into upper targets. #coo | #healthcare | #medtech | #stocktrading | #technicalanalysis | #hovdid
View on StockTwits ↗$COO global trends, fertility tech for later marriage?
View on StockTwits ↗$BHC if anyone has a brain at $COO they would merge with $BLCO and hire Brent as ceo to take over and have him sell it for a large premium. Look at what he did with forest lab allergen and actavis. Merged all of them
View on StockTwits ↗$COO Current Stock Price: $68.86 Contracts to trade: $70.0 COO Jul 17 2026 Call Entry: $1.20 Exit: $2.33 ROI: 94% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗Fundamental analysis of $COO (COOPER COMPANIES, INC.) based on financial data and reported results. #COO
View on StockTwits ↗🚀 Bulls delivering on Friday June 12 with SpaceX IPO buzz, healthcare rotation, and small-cap explosions! 🐂📈 First off 🤑who’s all up late studying charts and getting ready for next week? Our group just received two new banger alerts that have serious 100-200% run potential. Eyes sharp, bulls! Huge congrats to everyone riding these top 5 movers today. $CASY +20.3% – Casey’s General Stores surging on strong Q4 earnings beat and raised full-year guidance. $COO +8.6% – Cooper Companies climbing on positive healthcare demand and sector rotation. $RGTI + momentum – Rigetti Computing riding quantum/AI tailwinds amid broader tech interest. $SPHL + high % – Springview Holdings lifting o $ABSI + biotech – Absci Corp gaining on AI-drug discovery news and clinical updates. Strong week close with records in play, bulls – keep that momentum rolling into next week! 💪 Who else is celebrating big gains today? Drop your winners below. #TopMovers #BullMarket #Stocks #BangerAlerts #HealthcareStocks
View on StockTwits ↗$COO Serious question: How many great companies have investors sold because of one disappointing guidance update? The market often reacts immediately. Fundamentals usually take longer to change. Do you pay more attention to guidance or long-term execution?
View on StockTwits ↗$COO is proving why it’s a high-quality compounder. Ten straight earnings beats and margin expansion that’s beating the MedTech average. The market’s "revenue guidance trim" was a knee-jerk reaction to APAC softness, but the operational leverage here is the real story. Watch for $75 as the next big test for this breakout. 🐂 Bull Level: Reclaim $75.00 to confirm the move back toward historical highs. 🐻 Bear Level: $64.00 is the non-negotiable floor for the current trend. #COO #CooperCompanies #MedTech #EarningsBeat #hovdid
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.